Abstract Rationale: Schizophrenia is a heterogeneous syndrome both at the etiological and clinical levels. In particular, patients with schizophrenia exhibit important variability in their therapeutic and metabolic responses to clozapine, an antipsychotic medication. Objective: Here, we determine whether two mouse strains show differing clozapine responses with respect to weight gain, enhancement of prepulse inhibition of acoustic startle, and reversal of amphetamine-induced locomotion. Observed between-strain differences may be partly due to genetic factors that can be subsequently mapped using quantitative genetic approaches. Methods: We treated the A/J and C57BL/6J inbred mouse strains with clozapine for 22 days. Prepulse inhibition and amphetamine-induced locomotion were measured after 3-4 days of clozapine treatment and again after 21-22 days of treatment. Weight gain was also monitored during treatment. Results: Threeday treatment with clozapine increased prepulse inhibition in both strains. Four-day clozapine treatment reduced amphetamine-induced locomotion only in the C57BL/6J strain. Long-term (21-22 days) clozapine treatment did not affect these behaviors in either strain. After an initial weight loss during the first 5 days, clozapine (4 mg/kg) induced a significant weight gain in both strains. Conclusions: The reversal of schizophrenia-related behaviors after short-term, but not long-term, clozapine treatment is consistent with other rodent studies. Although short-term clozapine treatment reduced amphetamine-induced locomotion only in the C57BL/6J strain, strain differences in amphetamine responses confound the interpretation of these results; therefore, quantitative genetic approaches may be difficult to carry out with this trait. In contrast, enhancement of prepulse inhibition after three days of clozapine treatment and weight gain induced by clozapine are relatively straightforward to quantify, making these trait more amenable to quantitative genetic approaches.
Introduction
Schizophrenia, a chronic and debilitating psychiatric disorder characterized by symptom heterogeneity, affects approximately 1% of the worldwide population. The treatment of schizophrenia includes various forms of psychosocial interventions coupled with antipsychotic medication. Therapeutic response to antipsychotic drugs is highly variable from one patient to the other, with some patients showing very poor response to medication. Compared to the so-called typical antipsychotic medications (e.g. chlorpromazine, haloperidol), clozapine, an atypical antipsychotic drug, has been proven to be effective in patients with refractory symptoms (Kane et al. 1988) . Clozapine improves both positive and negative symptoms of schizophrenia, whereas typical antipsychotics primarily treat positive symptoms (Kane et al. 1988; Buchanan 1995) . Clozapine use is also associated with significant weight gain (Buchanan 1995) , which is considered both a serious health risk (Allison et al. 1999; Blin and Micallef 2001) and a major reason for noncompliance with treatment (Fleischhacker et al. 1994) . Nevertheless, some studies have suggested that weight gain and therapeutic response resulting from clozapine treatment may be correlated (Leadbetter et al. 1992; Czobor et al. 2002; Meltzer et al. 2003) .
Therapeutic responses and weight gain profiles vary considerably among clozapine-treated patients (Rietschel et al. 1997; Masellis et al. 1998; Arranz et al. 2000; Theisen et al. 2001) . While the variability of therapeutic response to clozapine is a well-established clinical fact, the predictors and correlates of this variability are poorly understood. Clinical studies have suggested that allelic variance in receptor-coding genes may contribute to the variability in responses to clozapine (Rietschel et al. 1997; Masellis et al. 1998; Basile et al. 2001) . However, different methods and measures have resulted in inconsistent findings among these studies.
Since experimental methods can be more controlled in animal experiments, the present study was designed to assess potential genetic differences in behavioral and metabolic (i.e. weight gain) responses to clozapine in the A/J and C57BL/6J inbred mouse strains. The A/J and C57BL/6J inbred mouse strains have shown differing phenotypes for several characteristics, including prepulse inhibition of acoustic startle (Joober et al. 2002) , weight gain and diabetes (Surwit et al. 1995) , running responses to cocaine (Shuster et al. 1977) , and motor activity (Gendreau et al. 1998 ). Mice were used for this study because this species provides an array of tools for eventual mapping of genes modulating clozapine responses. Such tools include recombinant inbred, recombinant congenic, and chromosome substitution strains derived from A/J and C57BL/6J parents (Nadeau et al. 2000; Fortin et al. 2001; Prows and Horner 2002) .
We employed two behavioral paradigms to model the therapeutic potential of clozapine: reversal of amphetamine (AMPH)-induced locomotion and enhancement of prepulse inhibition of acoustic startle. In rodents, AMPHinduced locomotion has often been used as a behavioral indicator of overactivity in the mesolimbic dopamine pathway (Kelly and Iversen 1976; Segal and Kuczenski 1987) , which is putatively implicated in the genesis of positive symptoms of schizophrenia (Laruelle and AbiDargham 1999) . This paradigm has been used to test proposed factors that may increase vulnerability to schizophrenia (Henry et al. 1995; El-Khodor and Boksa 1998) and to test neural substrates possibly involved in the development of schizophrenia (Lipska et al. 1993) . Clinically effective antipsychotic drugs have been shown to reduce AMPH-induced locomotion (Sams-Dodd 1998; Andersen and Pouzet 2001) . In these studies, rats were treated with antipsychotics for 21 days to model longterm treatment in humans, and drug effects were assessed after 3 and 21 days of treatment. While Sams-Dodd (1998) found that clozapine reduced AMPH-induced locomotion at both time points, Andersen and Pouzet (2001) found that AMPH-induced locomotion decreased following only 3-day treatment with antipsychotics; this effect was lost with 21-day treatment. We therefore designed our experiment to determine whether short-term (3-4 day) clozapine treatment, as opposed to long-term (21-22 day) treatment, sufficiently induces behavioral changes that model therapeutic response in mice.
Within the last decade, many studies have focused on deficits in sensorimotor gating mechanisms in schizophrenia, such as prepulse inhibition (PPI) of acoustic startle . PPI occurs when a mild stimulus (i.e. the prepulse), presented 30-500 ms before a strong, startling stimulus, reduces the startle response to the second stimulus (Hoffman and Ison 1980; . Numerous studies have demonstrated that persons with schizophrenia or schizophrenia-spectrum disorders exhibit deficits in PPI Geyer et al. 1990; Braff et al. 2001) . PPI is a cross-species phenomenon, and pharmacological agents (e.g. AMPH, apomorphine, and phencyclidine) have often been used to disrupt PPI in animals to model gating deficits observed in schizophrenia Varty and Higgins 1995) . Both typical and atypical antipsychotic drugs can reverse these pharmacologically induced disruptions in PPI (Rigdon and Viik 1991; Swerdlow and Geyer 1993; Hoffman and Donovan 1994; Swerdlow et al. 1994; Varty and Higgins 1995) . However, this disruption paradigm may not be ideal for studies of strain differences in antipsychotic effects, since strains may exhibit differing responses to both the antipsychotic and the drug used to disrupt PPI . Other methods of PPI disruption have therefore been sought. Comparison studies have determined that several inbred mouse strains exhibit naturally occurring differences in levels of PPI (Bullock et al. 1997; Paylor and Crawley 1997) . In addition, clozapine has already been shown to improve PPI in some (e.g. DBA/2J, BALB/cByJ), but not all (e.g. 129/EVEV), mouse strains (Olivier et al. 2001; Ouagazzal et al. 2001) . Rather than trying to correct a drug-induced disruption of PPI, we therefore used the A/J and C57BL/6J inbred mouse strains, shown to differ in levels of PPI (Joober et al. 2002) , to determine whether clozapine can enhance low PPI levels that are presumably genetic in origin.
The present study was designed to investigate three hypotheses: 1) the A/J and C57BL/6J inbred mouse strains differ in their behavioral and metabolic responses to clozapine, suggesting that responses to clozapine are partially under genetic control; 2) under clozapine treatment, weight gain may be associated with behavioral responses that are often used as indices of therapeutic response in humans; 3) short-term treatment with clozapine in mice is sufficient to induce behavioral changes that model therapeutic response. To test these hypotheses, we compared the effects of short-term (3-4 day) and longterm (21-22 day) clozapine treatment on AMPH-induced locomotion, PPI, and weight gain in male A/J and C57BL/ 6J mice.
Materials and methods

Animals
All mice originated from RGS Genome Inc., Montreal, Canada. They were housed in an animal room kept at 20-22C, with a relative humidity of 40% and a 12-h light cycle (lights on 0800-2000 hours). Animals had free access to standard mouse chow and water. We used a total of 122 male A/J and C57BL/6J mice (6-8 weeks old). They were allowed a minimum of 3 days to acclimatize to the new facility before beginning clozapine treatment. Within each housing group (4-12 per cage), animals in each strain were evenly distributed among the four treatment groups.
All procedures with animals were performed in accordance with guidelines from the Canadian Council on Animal Care and were approved by the McGill University Animal Care Committee.
Drug solutions
Clozapine (mol. wt 326.8; Alexis Biochemicals, San Diego, Calif., USA) was dissolved in 5 N HCl, adjusted to pH 7 with 0.1 N NaOH, and brought to final volume with 0.9% sterile saline. Vehicle solution consisted of 0.9% sterile saline with the same amount of 5 N HCl used to dissolve the clozapine and brought to a final pH of 7 with 0.1 N NaOH. Dexamphetamine sulphate was dissolved in 0.9% sterile saline (mol. wt 368.5; Sigma-Aldrich Corp., St Louis, Mo., USA). All injections were delivered in a volume of 10 ml/kg.
The following experimental design allowed us to test the effects of short-term (3-4 day) and long-term (21-22 day) clozapine treatment on PPI, AMPH-induced locomotion, and weight gain in male A/J and C57BL/6J mice.
Mice in both strains were randomly assigned to one of four treatment groups: control, vehicle and clozapine (2 mg/kg per day or 4 mg/kg per day). In order to determine the basic strain-specific characteristics in the two behavioral paradigms and weight gain, the control group received no injections or manipulation, except for AMPH on testing days 4 and 22. Vehicle-treated mice were used as a second control group to observe the effects of handling and injection stresses on behavior and weight gain. On days 1 and 2, treated animals received one daily intraperitoneal injection of either vehicle or clozapine. On day 3, mice received their respective treatments (vehicle, clozapine, or none) and were placed in the startle apparatus 1 h later for PPI tests. After testing was completed, the mice were placed in the locomotor apparatus for 1 h of habituation. The following day (day 4), the mice received their respective treatments 1 h prior to being tested for AMPH-induced locomotor activity for 2 h. During the next 14 days, the mice were given their respective treatments (vehicle, clozapine, or none) on a daily basis and weighed to monitor weight gain associated with chronic treatment. On days 21 and 22, the mice were once again tested for PPI and AMPH-induced locomotion, respectively.
Sams-Dodd (1998) has shown that the time delay between a daily clozapine injection and behavioral testing affects behavioral responses, even in experiments with chronic clozapine treatment. Thus in our experiment, behavioral testing always took place 1 h after the daily clozapine injection. In addition, on the 2 days previous to behavioral testing (days 1 and 2; days 19 and 20), clozapine injections were scheduled to be administered at the same time of day that the animal would receive clozapine on the day of behavioral testing.
Prepulse inhibition of acoustic startle
Two identical SR-LAB startle response chambers were used for startle testing (San Diego Instruments, San Diego, Calif., USA). Each sound-attenuated and ventilated chamber contained a Plexiglas cylinder whose inner diameter (3.8 cm) and length (6.5 cm) restricted movement. The cylinder sat atop a piezoelectric transducer that detected vibrations caused by the mouse's movements.
Regular calibrations were performed to maintain consistent recording sensitivity between chambers and across testing days. An SR-LAB Control 281 sound generating system produced all acoustic stimuli. A Radio Shack digital sound level meter (A scale) was used to calibrate sound intensity within the chambers. A microcomputer control unit controlled the timing and presentation of acoustic stimuli; this control unit also digitized and stored startle responses to the stimuli. Startle amplitude, measured in arbitrary units, was determined by the average of 65 readings taken at 1-ms intervals, beginning at stimulus onset.
Startle testing took place between 0900 and 1530 hours. The 16-min testing session consisted of three phases. First, 70-dB white noise was presented for 5 min to acclimatize the mouse to the apparatus; this stimulus continued throughout the session as background noise. Next, one pulse-alone trial (120 dB, 30 ms) was presented to orient the mouse. Data from this trial were excluded from subsequent analyses. Six blocks of trials then followed, with each block containing two pulse-alone trials (P), five prepulse+pulse trials (PP+P), and one presentation of 70-dB background noise (null) delivered in pseudo-random order; the average intertrial interval was 17 s (range: 9-29 s). The five PP+P trials consisted of a 30-ms prepulse of 75, 80, 85, 90, or 95 dB followed by a 70-ms delay and then a startle pulse (120 dB, 30 ms).
Null trials were presented to determine the mouse's baseline movement in the testing chamber. The average responses to the six null trials were low and did not differ between strains or treatment conditions (all P>0.7) at both 3 and 21 days. For each animal, the average response to the six null trials was subtracted from all startle amplitudes resulting from both the P and PP+P trials. The startle amplitudes elicited by the 12 P trials were averaged to obtain the average startle response (ASR). Percentage of prepulse inhibition was calculated with the following formula: [1(startle amplitude on PP+P trial/ASR)]100.
Locomotor testing
Locomotor activity was recorded in activity chambers (17.810.426.5 cm) equipped with two infrared beams. Locomotor activity counts were recorded when the two parallel infrared beams were interrupted consecutively. Beam interruptions in each box were monitored and stored by a computer. Each mouse was habituated to the locomotor apparatus for 1 h, 1 day prior to locomotor testing. Locomotor testing occurred between 0900 and 1800 hours. On testing days, all mice were injected with dexamphetamine sulphate (5 mg/kg sc: dose calculated as the salt) exactly 1 h after their respective treatments (vehicle, clozapine, or none) and immediately placed in the locomotor apparatus for a 2-h testing period.
Data analyses
Mice were excluded from data analyses if they did not complete the testing period due to equipment failure, experimental error, or death. For PPI analyses, mice were also excluded if their mean startle values were more than 1.5 SD below the mean for their strain, regardless of treatment group; this excluded three mice in the C57BL/6J strain (one vehicle-treated mouse and two mice treated with 4 mg/kg clozapine). In total, 16 male mice (122 originally in the study) were excluded from PPI analyses; the final numbers ranged from 12 to 14 mice in each treatment group for each strain. Eighteen out of 122 male mice were excluded from locomotor analyses; the final numbers ranged from 12 to 14 mice in each treatment group for each strain. For weight gain analyses, three out of 122 male mice were excluded due to either sickness or death; the final numbers of mice in each treatment group for each strain ranged from 13 to 16.
Since behavioral testing occurred over a large span of time (October 2000 to April 2001), we assessed the reliability of the behavioral measures both across time and within each of the eight treatment groups (four treatmentstwo strains). Using mid-January 2001 as a cut-off point, male mice in each treatment group were divided into early-and late-tested sets for time comparisons. For between-subject comparisons, mice were sequentially numbered within each treatment group and then separated into odd-and evennumbered sets, irrespective of testing time. To test reliability in PPI recordings across the two testing chambers, mice in each treatment group were categorized according to their startle chamber to determine any chamber effects. Independent t-tests were performed on the time-, number-, and chamber-divided sets to assess reliability. When the alpha level was corrected for the number of comparisons performed on the data, no significant time, number, or chamber effects were discovered.
For locomotor analyses, the locomotor activity counts recorded over the 120-min testing period were separated into 10-min bins to assess activity trends over time. For each treatment group in each strain, we also determined the areas under the locomotor activity curves as a representation of overall locomotor activity throughout the testing period.
While we did not test the effects of clozapine on baseline locomotor activity in the absence of AMPH, we noticed that the mice were less active after clozapine treatment. During locomotor testing, the early sedative effects of clozapine may have interfered with both habituation and AMPH-induced locomotion. Therefore, two-way analyses of covariance (ANCOVA) were performed; the locomotor data during the habituation period were used as the covariate to correct for the sedation seen both in habituation and during AMPHinduced locomotion in the four treatment groups. Since an earlier experiment suggested that clozapine did not improve PPI via sedation (Depoortere et al. 1997 ), we did not statistically correct for sedation in PPI analyses. Two-way analyses of variance (ANOVA) were performed on the ASR data to assess effects of strain and treatment on startle responses. Three-way ANOVAs for repeated measures were performed on the PPI and weight gain data in the four treatment groups to assess effects of strain, treatment, and either prepulse intensity or day, respectively. Simple effects tests were used to analyze significant interactions, and Tukey's honest significant difference test was used for post-hoc analyses.
Results
We assessed clozapine's effects on ASR, PPI, and AMPH-induced locomotion in male A/J and C57BL/6J mice after 3-4 and 21-22 days of treatment. Between the two behavioral testing periods, weight gain under clozapine treatment was observed over a 14-day period.
Average startle response and prepulse inhibition: 3 days Table 1 shows data for ASR in male A/J and C57BL/6J mice after 3 days of clozapine treatment. A two-way ANOVA (straintreatment) on the ASR obtained from 12 startle trials revealed significant main effects of strain Table 1 Average startle responses (ASR) €SEM (measured in arbitrary units) after short-term (3-day) and long-term (21-day) clozapine treatment in male A/J and C57BL/6J mice are shown. At both time points, A/J mice had lower startle responses than C57BL/6J mice, regardless of treatment (denoted by #, all P<0.01).
Both A/J and C57BL/6J mice treated with 4 mg/kg clozapine for 3 days had lower startle responses compared to mice of the same strain receiving either no treatment, vehicle, or 2 mg/kg clozapine (denoted by *, all P<0.05) Table 2 shows data for PPI in male A/J and C57BL/6J mice after 3 days of clozapine treatment. A three-way repeated measures ANOVA (straintreatmentprepulse intensity) was performed on the average data resulting from six presentations of each of the five prepulse+pulse trial types (75-, 80-, 85-, 90-, and 95-dB prepulses) . The ANOVA revealed a significant treatment effect [F(3,98)= 4.50; P<0.01] and a significant prepulse intensity effect [F(4,392)=16.10; P<0.01]. Post-hoc analysis of the treatment factor determined that mice treated with 4 mg/kg clozapine (n=26) had significantly higher PPI than mice treated with either vehicle (n=27) or 2 mg/kg clozapine (n=26), in both strains and across all prepulse intensities (all P<0.05). Post-hoc tests on the significant prepulse intensity factor showed that a 75-dB prepulse elicited significantly lower PPI in all mice than did all other prepulse intensities (all P<0.01). Post-hoc tests also revealed that a prepulse of 95 dB elicited higher PPI in all mice compared to prepulses of either 75 or 80 dB (all P<0.01). Since there is a possibility that the 95-dB prepulse may elicit a startle response on its own, we re-analyzed the data without including the 95-dB prepulse trials. The ANOVA again revealed both a significant treatment effect [F(3,98)=5.311; P<0.01] and a significant prepulse intensity effect [F(3,294)=12.811; P<0.01]. Post-hoc tests on the treatment factor showed that mice treated with 4 mg/kg clozapine (n=26) still had higher PPI than mice treated with either vehicle (n=27) or 2 mg/kg clozapine (n=26), in both strains and across all prepulse intensities (all P<0.01). Post-hoc analysis of the significant prepulse intensity factor again determined that the 75-dB prepulse elicited significantly lower PPI in all mice than did all other prepulse intensities (all P<0.01).
Since no significant strain-by-treatment interaction was found at any prepulse intensity [F(12,392)=0.94; P>0.5], we may conclude that short-term (3-day) clozapine treatment did not affect PPI differently in the two inbred mouse strains.
Average startle response and prepulse inhibition: 21 days Table 1 shows data for ASR in male A/J and C57BL/6J mice after 21 days of clozapine treatment. A two-way ANOVA resulted only in a significant strain effect [F(1,98)=43.51; P<0.01], which indicated that A/J mice had lower startle responses than C57BL/6J mice. The lack of a significant treatment effect or a strain-by-treatment interaction indicates that clozapine did not affect startle responses after 21 days of treatment.
A three-way repeated measures ANOVA on the PPI data after 21 days of clozapine treatment revealed no significant three-way interaction, no strain-by-treatment interaction, and no significant main effects (Table 2 ). These results suggest that long-term (21-day) clozapine treatment did not globally affect PPI in the two inbred mouse strains. Figure 1a shows locomotor activity assessed for 120 min after AMPH (5 mg/kg) administration in male A/J and Fig. 1 a Patterns of AMPH-induced locomotion after short-term (4-day) clozapine treatment in male A/J and C57BL/6J mice. Data points represent mean locomotor activity counts+SEM, assessed for 120 min after AMPH administration. The two inbred mouse strains have contrasting AMPH response profiles (P<0.05). The A/J strain's activity counts peak at 20 min and then sharply decline, while the C57BL/6J strain's activity counts peak at approximately 40 min and decline at a much slower rate. b AMPH-induced locomotion expressed as area under the AMPH-induced locomotion curve. Data in a were used to express AMPH-induced locomotion as mean area under the AMPH-induced locomotion curve+SEM for each treatment group in each strain. C57BL/6J mice treated with either clozapine dose had lower AMPH-induced locomotor activity than control or vehicle-treated C57BL/6J mice (denoted by *, P<0.01). No treatment effects were seen within the A/J strain. However, A/J mice in all treatment groups had lower AMPHinduced locomotion than C57BL/6J mice receiving either no, vehicle, or clozapine (2 mg/kg) treatment (denoted by #, P<0.01). CLOZ clozapine C57BL/6J mice that had received 4 days of clozapine treatment. A three-way repeated measures ANOVA on the activity counts across the testing session revealed a significant three-way interaction between strain, treatment, and time [F(33,1056)=1.52; P<0.05]. Simple effects tests revealed a strain difference in AMPHinduced locomotion across all treatment groups throughout the majority of the 120-min testing session [F(1,1152)!4.48; all P<0.05]. Post-hoc tests revealed that at 10 min, A/J mice treated with 4 mg/kg clozapine had lower AMPH-induced locomotion than A/J mice treated with 2 mg/kg clozapine (P<0.05). At 20 min, A/J mice treated with 4 mg/kg clozapine had significantly lower AMPH-induced locomotion than both A/J controls and A/J mice treated with 2 mg/kg clozapine (all P<0.01). Simple effects analyses also revealed treatment differences among the C57BL/6J mice in AMPH-induced locomotor activity recorded from 20 to 120 min [F(3,1152)!7.84; all P<0.01] . This indicates that for the majority of the testing session, treatment effects were only seen in the C57BL/6J strain. Fig. 1a reveals that these results may be due to very different time courses of AMPH response in the two inbred mouse strains. In the A/ J strain, AMPH increased locomotion up to 20 min and then lost its effect shortly thereafter when locomotor activity counts dropped sharply to almost baseline levels. In C57BL/6J mice, AMPH effects peaked at around 40 min and then slowly declined. At the end of the 120-min testing session, locomotor activity had not yet dropped to baseline levels in the C57BL/6J mice.
AMPH-induced locomotion: 4 days
We performed subsequent analyses on the areas under the locomotion curves (Fig. 1b) , since these areas better represent overall AMPH-induced locomotor activity. A two-way analysis of covariance (ANCOVA) was performed on the areas under the AMPH-induced locomotion curve, with the areas under the habituation curves used as the covariate to correct for clozapine's early sedative effects on locomotion. We found a significant two-way interaction between strain and treatment [F(3,95)=9.35; P<0.01]. Post-hoc tests on this interaction revealed that C57BL/6J mice receiving either 2 mg/kg (n=12) or 4 mg/ kg clozapine (n=13) had significantly lower AMPHinduced locomotion compared to C57BL/6J mice receiving either vehicle (n=13) or no treatment (n=13; all P<0.01). No treatment effects were seen among the A/J mice (all P>0.9). However, A/J mice in all treatment groups had lower AMPH-induced locomotor activity than C57BL/6J mice receiving either 2 mg/kg clozapine, vehicle, or no treatment (all P<0.01). These results suggest that short-term clozapine treatment differentially affected AMPH-induced locomotion in the two mouse strains. Clozapine treatment significantly reduced AMPHinduced locomotion in the C57BL/6J strain, while it had no effect on the A/J strain. Figure 2 shows AMPH-induced locomotor activity expressed as area under the AMPH-induced locomotion curve in male A/J and C57BL/6J mice after 22 days of clozapine treatment. We performed a two-way ANCOVA on the areas under the AMPH-induced locomotion curves, with the areas under the habituation curves used as the covariate to correct for clozapine's sedative effects on locomotion. The ANCOVA yielded only a significant strain effect [F(1,95)=34.74; P<0.01], indicating that A/J mice had lower locomotor activity than C57BL/6J mice in response to AMPH administration. No significant treatment effect or strain-by-treatment interaction was found. These results indicate that clozapine did not affect AMPH-induced locomotion after long-term (22-day) treatment in either mouse strain.
AMPH-induced locomotion: 22 days
Weight change
Figures 3a and 3b show weight change in male A/J and C57BL/6J mice during 18 days of clozapine treatment. A one-way ANOVA performed on the weight change from day 0 (day before experiment began) to day 5 (day after first behavioral testing session) revealed that both mouse strains lost weight after the first battery of behavioral tests, relative to day 0 (insets to Fig. 3a, b) . This weight loss may be due to the stress of the behavioral test battery. The A/J strain lost more weight than the C57BL/6J strain, irrespective of treatment [F(1,111)=35.49; P<0.01].
Weights were recorded daily for 14 days (days 5-18) between behavioral testing sessions to assess the effects of clozapine treatment, in the absence of any other manipulation, on weight. Daily weight changes were calculated relative to weights recorded on day 5. Weight   Fig. 2 AMPH-induced locomotion, expressed as area under the AMPH-induced locomotion curve, after long-term (22-day) clozapine treatment in male A/J and C57BL/6J mice. Bars represent the mean areas under the AMPH-induced locomotor activity curve+-SEM for each treatment group in each strain. The A/J strain had lower AMPH-induced locomotor activity than the C57BL/6J strain across all treatment groups (denoted by #, P<0.01). No treatment effects or strain-by-treatment interaction were found on day 5 was chosen as the baseline reference weight to correct for initial weight loss during behavioral testing on days 3-4. A three-way ANOVA for repeated measures resulted in significant main effects of strain [F(1,111)=5.141; P<0.05] and day [F(12,1332) =48.002; P<0.01], but no significant treatment effect or strain-bytreatment interaction was found (all P>0.06). The A/J strain (n=61) gained more weight than the C57BL/6J strain (n=58) over the 14-day period, and post-hoc analysis on the day factor determined that there was significant weight gain on an almost-daily basis (Fig. 3a,  b ; all P<0.05).
Although animals from both strains receiving 4 mg/kg clozapine showed the highest weight gain, the overall ANOVA including the four experimental groups did not show a significant treatment effect (P>0.05). Because stress may be an important factor in weight changes, we re-conducted analyses of weight gain data (days 5-18) after excluding the control group, which was subjected to much less experimental manipulation than the other three groups (vehicle, 2 mg/kg, and 4 mg/kg clozapine treatment groups, Fig. 3c) . A three-way repeated measures ANOVA revealed both a significant treatment effect [F(2,83)=3.383; P<0.05] and a significant day effect [F(12,996)=36.422; P<0.01]. Post-hoc tests on the treatment factor showed that across the 2-week observation period, mice treated with 4 mg/kg clozapine had significantly higher weight gain than mice treated with vehicle, regardless of strain ( Fig. 3c; P<0 .05). Weight gain induced by 2 mg/kg clozapine was at an intermediate level. Again, post-hoc tests on the day factor determined a significant weight gain on an almost-daily basis (all P<0.05). Although the higher clozapine dose induced the largest amount of weight gain compared to vehicle administration, clozapine treatment did not differentially affect weight gain between the two mouse strains.
Discussion
The main findings of our studies are: 1) short-term treatment with 4 mg/kg clozapine increased PPI and decreased ASR in both the A/J and C57BL/6J mouse strains; 2) short-term treatment with clozapine reduced AMPH-induced locomotion only in C57BL/6J mice, but not in A/J mice; 3) long-term treatment with clozapine did not alter PPI or AMPH-induced locomotion in either strain; 4) after five initial days of weight loss, mice receiving 4 mg/kg clozapine gained significantly more weight compared to mice receiving vehicle in both strains. Fig. 3 Weight changes in male (a) A/J and (b) C57BL/6J mice during long-term treatment with clozapine. Mice were untreated (control) or received one intraperitoneal injection of vehicle or clozapine (2 mg/kg or 4 mg/kg) per day for 21 days. Data points for days 6-18 show mean weight change relative to weight on day 5+SEM. Insets show weight change on day 5 relative to day 0. After the first 4 days of injections and behavioral tests, all mice lost weight, but A/J mice lost more than C57BL/6J mice, regardless of treatment (denoted by *, P<0.01); this weight loss may be due to the stress of the test battery. Subsequent weight changes from days 6-18 were calculated relative to each individual animal's weight on day 5 to correct for the differential between-strain weight loss during behavioral testing on days 3-4. By day 18, all mice gained weight relative to their weight at day 5; A/J mice gained more weight than C57BL/6J mice over the 2-week period from day 5-18 (denoted by #, P<0.05). c Mean weight gain in male A/J and C57BL/6J mice following long-term treatment with clozapine. Bars represent mean weight change (relative to day 5)+SEM, collapsed across the entire 2-week weight observation period (days 5-18). In both strains, mice treated with 4 mg/kg clozapine gained more weight than did mice treated with vehicle (P<0.05)
Our results indicate that only short-term (3-4 days) clozapine treatment in mice improved PPI and reduced AMPH-induced locomotion, two proposed indices of therapeutic response. With a longer course of treatment (21-22 days), effects of clozapine on these behaviors were absent. The absence of behavioral responses to longterm clozapine treatment in mice complements studies in rats by Andersen and Pouzet (2001) and Martinez et al. (2000) . These studies observed robust reversal of dopamine-agonist-induced behaviors after short-term treatment with either haloperidol or atypical antipsychotics (olanzapine and sertindole). Furthermore, the Andersen and Pouzet study (2001) determined that 3-day treatment with antipsychotics was more effective than a single acute injection in reversing AMPH-induced behavioral changes. However, after long-term treatment (21 days or more) with antipsychotics, the ability to reverse the effects of dopamine agonists either decreased or disappeared altogether. Thus it appears that in rodent models, antipsychotic treatment induces changes that may render targeted neurotransmitter or other systems less responsive to antipsychotics over time. For example, chronic (21-28 days) clozapine treatment has been shown to increase levels of dopamine D 1 and AMPA receptors in the nucleus accumbens, dorsal striatum, and other regions of the rat brain (O'Dell et al. 1990; See et al. 1990; Spurney et al. 1999) . Since D 1 and AMPA receptor activation have both been reported to reduce PPI in rodents (Wan et al. 1995; Geyer et al. 2001 , Ralph-Williams et al. 2002 , long-term increases in these receptors might counteract the early enhancement of PPI by clozapine. Similarly, activation of nucleus accumbens D 1 or AMPA receptors can enhance locomotion (Dreher and Jackson 1989; Willins et al. 1992; Boldry et al. 1993) . Thus, increases in these receptors induced by long-term clozapine treatment could conceivably counteract the ability of shortterm clozapine treatment to inhibit AMPH-induced locomotion.
Short-term treatment with clozapine increased PPI only at a dose (4 mg/kg) which also decreased ASR in both strains of mice. Previous studies concur that clozapine administered in single acute doses (3-30 mg/ kg) decreases ASR in C57BL/6J and other mouse strains (McCaughran et al. 1997; Olivier et al. 2001; Ouagazzal et al. 2001) . While the clozapine-induced decrease in startle response must be considered as a potential confound producing a spurious change in PPI, numerous examples of dissociations between changes in ASR and PPI suggest that the two measures are independent (McCaughran et al. 1997; Paylor and Crawley 1997; Olivier et al. 2001; Ouagazzal et al. 2001) . For example, Paylor and Crawley (1997) have shown that there is no correlation between levels of PPI and ASR across 13 strains of mice that vary in these parameters. As another example, McCaughran et al. (1997) have shown that a single injection of haloperidol, at a dose that increases PPI in both C57BL/6J and DBA/2J mice, increases average startle in the C57BL/6J mice but has no effect on average startle in the DBA/2J strain. In our study, it is highly unlikely that the clozapine-induced increase in PPI could be an artefact of clozapine's reduction of acoustic startle for the following reasons. If changes in PPI were due solely to changes in ASR (rather than due to changes in the PP+P startle amplitude), then a positive correlation between PPI and ASR would be mathematically predicted due to the proportional relationship between ASR and PPI (i.e. reduced ASR would result in reduced PPI; see formula for percentage of PPI in Materials and methods section). However, the opposite overall relationship was observed with 3-day clozapine treatment: clozapine reduced ASR but increased PPI. Furthermore, in our study, detailed correlational analyses between startle and PPI across prepulse intensities (except 95 dB) only revealed significant negative correlations between ASR and PPI at some prepulse intensities (75, 80, and 85 dB in the A/J strain; 75 dB in the C57BL/6J strain) on day 3, rather than positive correlations. These correlations could suggest that similar mechanisms might be responsible for clozapine-induced reductions in ASR and increases in PPI at these prepulse intensities, such that the two phenomena are seen together. However, since these correlations are negative, the changes in PPI are not due to changes in ASR. Since no correlations were found between PPI and ASR at several prepulse intensities on day 3 (90 dB for A/ J; 80, 85, 90 dB for C57BL/6J) and at all prepulse intensities on day 21, these two measures may be independent under some conditions. Taken together, these observations and the data from the literature suggest that the effect of clozapine on PPI cannot be attributed to its effect on startle.
Effects of clozapine on PPI in the A/J and C57BL/6J inbred mouse strains were similar, with respect to both time course of treatment and effective dose of clozapine required to enhance PPI. This may suggest that there are no genetic differences underlying clozapine modulation of PPI in these two inbred mouse strains. However, one cannot exclude the possibility that the random fixation of divergent alleles at a number of genetic loci during the inbreeding process might lead to phenotypically similar levels of these traits in the two strains. Further experiments with recombinant congenic strains (RCS) derived from A/J and C57BL/6J parents may be informative in this respect, since the RCS system transforms a multigenic trait into a series of single gene traits, thus allowing individual contributing genes to be mapped and studied separately (DØmant and Hart 1986; Groot et al. 1992; Fortin et al. 2001) .
Three previous studies have examined effects of single injections of clozapine on PPI in different inbred mouse strains, in efforts to identify strains with differential responses to clozapine. In two of these studies, no strainby-treatment interactions were found, indicating that clozapine enhanced PPI in all the strains tested (McCaughran et al. 1997; Olivier et al. 2001) . Examination of the data presented in these studies indicated that the order of strains with respect to effectiveness of clozapine enhancement of PPI appeared to be: DBA/2>C57BL/6J (McCaughran et al. 1997) , DBA/2J>C57BL/6J>129S6/ SvEvTac (Olivier et al. 2001) , and C57BL/6J>BALB/ cByJ>MORO>129/SvEv (Ouagazzal et al. 2001 ). Thus overall, there appears to be some strain variation in the degree of responsiveness of PPI to single injections of clozapine, although the modest effect of clozapine in strains with high baseline PPI may be due to a ceiling effect. It would be of interest to compare effects of clozapine on PPI in additional mouse strains with low baseline PPI (Bullock et al. 1997; Paylor and Crawley 1997) in a paradigm in which clozapine is administered on a repeated short-term basis (3-4 days).
Short-term clozapine treatment differentially affected AMPH-induced locomotion in A/J and C57BL/6J mice. The C57BL/6J strain experienced a significant decrease in AMPH-induced locomotion under clozapine treatment, while the A/J strain did not. This suggests that these two mouse strains may possess allelic differences in genes determining effects of clozapine on this behavior. However, A/J and C57BL/6J mice also displayed significantly different locomotor responses to AMPH administration. Clearly, in an experiment that compares clozapine effects across numerous mouse strains (e.g. recombinant inbred or recombinant congenic panels), between-strain differences in AMPH-induced locomotion will complicate calculations of the magnitude of clozapine effects on the AMPH response across strains. Therefore, PPI may be a more practical paradigm than AMPH-induced locomotion for investigating strain differences relevant to therapeutic response to clozapine.
Our weight gain results indicate that all mice lost weight in the first five days and recuperated from this weight loss thereafter. However, A/J and C57BL/6J mice may differ with respect to stress-induced effects on weight gain. A/J mice (irrespective of clozapine treatment) lost significantly more weight than C57BL/6J mice following the stress of behavioral testing on days 3 and 4. After behavioral testing, mice in both strains treated with 4 mg/kg clozapine gained significantly more weight compared to vehicle-treated mice; those receiving 2 mg/ kg clozapine showed an intermediate level of weight gain. Overall, these observations suggest that the dynamics of weight changes under clozapine are highly sensitive to stress and that weight gain under clozapine may be at least partially modeled in mice.
Interestingly, weight gain was more prominent, although not to a significant level, in the C57BL/6J compared to the A/J strain. Further experiments with recombinant congenic strains derived from the C57BL/6J and A/J parents may be warranted to reveal differential clozapine-induced weight gain due to genetic differences. Phenotypic differences in clozapine-induced weight gain may be more prominently expressed by using modified diets, such as a high fat diet reported to promote weight gain in A/J and C57BL/6J mice (Surwit et al. 1995; Brownlow et al. 1996) , or 10% sucrose-supplemented chow presented after 1 h of food deprivation (Kaur and Kulkarni 2002) .
Similar to the more prominent weight gain in C57BL/ 6J compared to A/J mice, it is the C57BL/6J strain that displayed robust behavioral modifications in both the PPI and the AMPH-induced locomotion paradigms. Although a formal correlation between clozapine-induced changes in PPI and weight gain cannot be performed (since we do not have a baseline evaluation of PPI before clozapine treatment), our experiments showed no evidence of a dissociation between these two effects of clozapine. By defining the clozapine dose (4 mg/kg) and treatment period (3 days) which significantly affects both an appropriate behavioral test (PPI) and weight gain in two inbred mouse strains, the present experiments lay the groundwork for further, more detailed experiments to evaluate correlations between effects of clozapine on putative therapeutic indices and weight gain.
